{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:33:31Z","timestamp":1781757211111,"version":"3.54.5"},"reference-count":32,"publisher":"Norwegian Medical Association","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2015,10,20]]},"DOI":"10.4045\/tidsskr.15.0049","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T01:56:12Z","timestamp":1445478972000},"page":"1745-9","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic complement inhibition \u2013 from experimental to clinical medicine"],"prefix":"10.4045","volume":"135","author":[{"given":"Knut Tore","family":"Lappeg\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bjerre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013; 190: 3831\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23564577&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4049\/jimmunol.1203487","DOI":"10.4049\/jimmunol.1203487"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058\u2009\u2013\u200966. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11287977&dopt=Abstract","DOI":"10.1056\/NEJM200104053441406"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140\u2009\u2013\u20094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11297706&dopt=Abstract","DOI":"10.1056\/NEJM200104123441506"},{"key":"ref=4","unstructured":"Nielsen EW. Heredit\u00e6rt angio\u00f8dem. Tidsskr Nor L\u00e6geforen 1989; 109: 1383\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2749621&dopt=Abstract"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 2013; 190: 3839\u2009\u2013\u200947. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23564578&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4049\/jimmunol.1203200","DOI":"10.4049\/jimmunol.1203200"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Risitano AM, Ricklin D, Huang Y et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094\u2009\u2013\u2009101. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24497537&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2013-11-536573","DOI":"10.1182\/blood-2013-11-536573"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233\u2009\u2013\u200943. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16990386&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa061648","DOI":"10.1056\/NEJMoa061648"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Melis JP, Strumane K, Ruuls SR et al. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol 2015; 67: 117\u2009\u2013\u200930. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25697848&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.molimm.2015.01.028","DOI":"10.1016\/j.molimm.2015.01.028"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol 2012; 40: 18\u2009\u2013\u200926. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22304025&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1442-9071.2011.02581.x","DOI":"10.1111\/j.1442-9071.2011.02581.x"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Nissen-Meyer LS, Tj\u00f8nnfjord GE, Golebiowska E et al. Paroksysmal nattlig hemoglobinuri ved Oslo universitetssykehus 2000\u2009\u2013\u200910. Tidsskr Nor Legeforen 2015; 135: 1039\u2009\u2013\u200943. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26080779&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045\/tidsskr.14.0444","DOI":"10.4045\/tidsskr.14.0444"},{"key":"ref=11","unstructured":"Tj\u00f8nnfjord EB, Tj\u00f8nnfjord GE. Nasjonale retningslinjer for PNH. http:\/\/legeforeningen.no\/Fagmed\/Norsk-selskap-for-hematologi\/Handlingsprogrammer\/ (21.8.2015)."},{"key":"ref=12","unstructured":"Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2015. E-publisert 11.4."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643\u2009\u2013\u200957. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23026949&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/nrneph.2012.214","DOI":"10.1038\/nrneph.2012.214"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Diamante Chiodini B, Davin JC, Corazza F et al. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 2014; 133: e1764\u2009\u2013\u20098.","DOI":"10.1542\/peds.2013-1594"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18055865&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2007-06-094136","DOI":"10.1182\/blood-2007-06-094136"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol 2013; 98: 406\u2009\u2013\u200916. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23934275&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s12185-013-1404-y","DOI":"10.1007\/s12185-013-1404-y"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Hillmen P, Muus P, R\u00f6th A et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162: 62\u2009\u2013\u200973. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23617322&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/bjh.12347","DOI":"10.1111\/bjh.12347"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Vilalta R, Lara E, Madrid A et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 2012; 27: 2323\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22890512&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00467-012-2276-8","DOI":"10.1007\/s00467-012-2276-8"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013; 24: 492\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23756030&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.ejim.2013.05.008","DOI":"10.1016\/j.ejim.2013.05.008"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Martel C, Granger CB, Ghitescu M et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2012; 164: 43\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22795281&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.ahj.2012.04.007","DOI":"10.1016\/j.ahj.2012.04.007"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Ghirardo G, Benetti E, Poli F et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014; 18: E1\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24266980&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/petr.12187","DOI":"10.1111\/petr.12187"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Lonze BE, Zachary AA, Magro CM et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14: 459\u2009\u2013\u200965. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24400968&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/ajt.12540","DOI":"10.1111\/ajt.12540"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Charles Jennette J, Xiao H, Hu P. Complement in ANCA-associated vasculitis. Semin Nephrol 2013; 33: 557\u2009\u2013\u200964. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24161040&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.semnephrol.2013.08.006","DOI":"10.1016\/j.semnephrol.2013.08.006"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Kusner LL, Satija N, Cheng G et al. Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve 2014; 49: 749\u2009\u2013\u200956. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24037951&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/mus.24057","DOI":"10.1002\/mus.24057"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Pittock SJ, Lennon VA, McKeon A et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554\u2009\u2013\u200962. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23623397&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S1474-4422(13)70076-0","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Sharp JA, Whitley PH, Cunnion KM et al. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol 2014; 5: 406. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25202312&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389\/fimmu.2014.00406","DOI":"10.3389\/fimmu.2014.00406"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Shi J, Rose EL, Singh A et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24695853&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2014-02-556027","DOI":"10.1182\/blood-2014-02-556027"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Macor P, Durigutto P, De Maso L et al. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum 2012; 64: 2559\u2009\u2013\u200967. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22334275&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/art.34430","DOI":"10.1002\/art.34430"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Dmytrijuk A, Robie-Suh K, Cohen MH et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13: 993\u2009\u2013\u20091000. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18784156&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1634\/theoncologist.2008-0086","DOI":"10.1634\/theoncologist.2008-0086"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006; 43: 107\u2009\u2013\u200921. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16011851&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.molimm.2005.06.014","DOI":"10.1016\/j.molimm.2005.06.014"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Falc\u00e3o DA, Reis ES, Paix\u00e3o-Cavalcante D et al. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9. Scand J Immunol 2008; 68: 445\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18782275&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-3083.2008.02152.x","DOI":"10.1111\/j.1365-3083.2008.02152.x"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Sprong T, Brandtzaeg P, Fung M et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003; 102: 3702\u2009\u2013\u200910. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12881318&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2003-03-0703","DOI":"10.1182\/blood-2003-03-0703"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Terapeutisk komplementhemming \u2013 fra eksperimentell til klinisk medisin"],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:30:30Z","timestamp":1781641830000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2015\/10\/klinisk-oversikt\/terapeutisk-komplementhemming-fra-eksperimentell-til-klinisk-medisin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":32,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015,10,20]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.15.0049","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}